Hospital
Columbia-Alleghany Regional Hospital INC
Columbia-Alleghany Regional Hospital INC was paid $9.82M by Medicaid between Jan 2018 and Dec 2024, across 148 billing codes. Its largest line is 99283, emergency room visit (moderate) — 33% of everything it billed.
33Billing provider infoCOLUMBIA-ALLEGHANY REGIONAL HOSPITAL INC
LOW MOOR, VA 24457
LOW MOOR, VA 24457
33aNPI1538100029assigned 06/08/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.82M
24GClaims296,573
24DCodes billed148
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#51 of 80
Median peer was paid$14.69M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 32,641 | $595K | |
| 2019 | 44,490 | $1.11M | |
| 2020 | 35,634 | $1.16M | |
| 2021 | 41,756 | $1.36M | |
| 2022 | 46,117 | $1.65M | |
| 2023 | 50,654 | $1.99M | |
| 2024incomplete | 45,281 | $1.96M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 33% | 20,850 | 17,426 | $3.24M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 11,574 | 9,518 | $1.55M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.0% | 4,890 | 4,367 | $790K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.3% | 4,516 | 3,682 | $617K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.8% | 2,914 | 2,535 | $468K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.2% | 2,939 | 2,427 | $408K |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.1% | 1,719 | 1,452 | $402K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.3% | 7,462 | 1,951 | $329K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.7% | 925 | 858 | $262K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.6% | 1,437 | 1,321 | $251K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.4% | 1,550 | 1,312 | $238K |
| G0378 | Hospital observation service, per hour | 1.8% | 2,014 | 1,053 | $181K |
136 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.3% | 3,663 | $131K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,631 | $78K |
| 80053 | Comprehensive metabolic panel | <1% | 17,966 | $75K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 311 | $67K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,890 | $61K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,162 | $59K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 582 | $52K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,674 | $44K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 392 | $34K |
| 85027 | <1% | 23,101 | $31K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 560 | $23K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,397 | $22K |
| 97161 | <1% | 243 | $20K | |
| 71045 | Radiologic examination, chest; single view | <1% | 6,819 | $19K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,562 | $18K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,822 | $17K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,464 | $17K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 725 | $16K |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,726 | $15K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 94 | $14K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 240 | $14K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 33 | $13K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,706 | $13K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,961 | $12K |
| 87040 | <1% | 2,261 | $12K | |
| 72100 | <1% | 596 | $11K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 640 | $11K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,622 | $10K |
| 80061 | Lipid panel | <1% | 3,198 | $9K |
| 73630 | <1% | 495 | $9K | |
| 93017 | <1% | 76 | $8K | |
| 84484 | <1% | 6,389 | $8K | |
| 83880 | <1% | 1,784 | $7K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 62 | $7K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 589 | $6K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 22 | $6K |
| 73030 | <1% | 396 | $6K | |
| 81001 | <1% | 8,176 | $5K | |
| 85379 | <1% | 1,308 | $5K | |
| 97164 | <1% | 25 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,449 | $5K |
| 73562 | <1% | 291 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,890 | $4K |
| 80076 | <1% | 1,941 | $4K | |
| 93971 | <1% | 38 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,709 | $3K |
| 83605 | <1% | 2,682 | $3K | |
| 73610 | <1% | 404 | $3K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 335 | $3K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,007 | $3K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 46 | $3K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,389 | $3K |
| 85610 | <1% | 4,170 | $2K | |
| 83735 | <1% | 4,125 | $2K | |
| 80143 | <1% | 753 | $2K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 400 | $2K |
| 97162 | <1% | 42 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,632 | $2K |
| 87070 | <1% | 2,289 | $2K | |
| 83690 | <1% | 4,690 | $2K | |
| 81003 | <1% | 3,855 | $2K | |
| 93246 | <1% | 41 | $2K | |
| 87420 | <1% | 570 | $2K | |
| 81025 | <1% | 3,442 | $2K | |
| 74018 | <1% | 79 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,725 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,976 | $1K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 4,615 | $1K |
| 80047 | <1% | 484 | $1K | |
| 80179 | <1% | 757 | $1K | |
| 87186 | <1% | 1,125 | $1K | |
| 72114 | <1% | 42 | $1K | |
| 76830 | Ultrasound, transvaginal | <1% | 12 | $982.51 |
| 73502 | <1% | 58 | $796.61 | |
| 85730 | <1% | 894 | $711.26 | |
| 93226 | <1% | 14 | $638.96 | |
| 86140 | <1% | 367 | $632.17 | |
| 84439 | <1% | 117 | $621.89 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,399 | $620.83 |
| 85652 | <1% | 307 | $587.18 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 504 | $582.79 |
| 96376 | <1% | 563 | $541.65 | |
| 72110 | <1% | 49 | $540.50 | |
| 74021 | <1% | 18 | $530.20 | |
| 82077 | <1% | 1,316 | $466.81 | |
| 84703 | <1% | 595 | $408.56 | |
| 90714 | <1% | 19 | $404.93 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 606 | $401.87 |
| 87077 | <1% | 770 | $373.09 | |
| 73110 | <1% | 25 | $344.50 | |
| 82607 | <1% | 27 | $291.00 | |
| 71250 | <1% | 13 | $281.05 | |
| 82550 | <1% | 820 | $272.13 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,390 | $233.82 |
| 84702 | <1% | 53 | $228.78 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,023 | $190.46 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 30 | $176.29 |
| 86850 | <1% | 50 | $132.78 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 74 | $128.72 |
| 73130 | <1% | 69 | $117.48 | |
| 82803 | <1% | 295 | $105.10 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,102 | $81.23 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 655 | $50.31 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 626 | $47.65 |
| 86900 | <1% | 29 | $42.03 | |
| 84100 | <1% | 50 | $40.56 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 103 | $23.51 |
| 86901 | <1% | 29 | $22.35 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 140 | $18.66 |
| 82248 | <1% | 30 | $17.85 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 446 | $15.83 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 372 | $15.68 |
| 87147 | <1% | 39 | $15.01 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 50 | $12.13 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 368 | $11.09 |
| J1815 | Injection, insulin, per 5 units | <1% | 334 | $8.06 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 34 | $5.44 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 134 | $3.34 |
| A9270 | Non-covered item or service | <1% | 2,837 | $3.20 |
| 82310 | <1% | 23 | $3.07 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 26 | $2.49 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 25 | $1.84 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 67 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 45 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 76 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 190 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 12 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 12 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 26 | $0.00 |
| J3490 | Unclassified drugs | 0% | 646 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 178 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 90 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 33 | $0.00 |
| 87081 | 0% | 33 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 70 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialREYNOLDS, ANGELA (CFO)
| Provider | Location | Paid |
|---|---|---|
| Lewis-Gale Medical Center, LLC | Salem, VA | $51.85M |
| Lewis-Gale Medical Center, LLC | Cave Spring, VA | $1.17M |
| Lewisgale Medical Center, LLC | Roanoke, VA | $413K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.